Trial Profile
An events of decompensation, clinical and biochemical improvement in patients with compensated and decompensated cirrhosis treated with sofosbuvir-based regimens.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jan 2017
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Liver cirrhosis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 06 Jan 2017 New trial record